Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer.

ABSTRACT: Increased ploidy is common in tumors but treatments for tumors with excess chromosome sets are not available. Here, we characterize high-ploidy breast cancers and identify potential anticancer compounds selective for the high-ploidy state. Among 354 human breast cancers, 10% have mean chromosome copy number exceeding 3, and this is most common in triple-negative and HER2-positive types. Women with high-ploidy breast cancers have higher risk of recurrence and death in two patient cohorts, demonstrating that it represents an important group for improved treatment. Because high-ploidy cancers are aneuploid, rather than triploid or tetraploid, we devised a two-step screen to identify selective compounds. The screen was designed to assure both external validity on diverse karyotypic backgrounds

SUBMITTER: Choudhary A 

PROVIDER: S-EPMC4707107 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature